Iovance Biotherapeutics IOVA
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$23.78M (7 inflow days, 13 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 29.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 22.73% to 14.39% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Van Eck Associates Corporation | Mutual Fund | 2026/Q3 | +184,099 | 0.0% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +1,259,960 | 0.7% |
| BlackRock | Mutual Fund | 2026/Q3 | +946,279 | 8.2% |
| Rhenman & Partners Asset Management AB | Hedge Fund | 2026/Q3 | +797,250 | 0.5% |
| Barclays PLC | Public Company | 2026/Q3 | +407,497 | 0.1% |
| Pictet Asset Management Limited | Mutual Fund | 2026/Q3 | +373,491 | 0.1% |
| FMR | Mutual Fund | 2026/Q3 | +353,918 | 0.4% |
| Russell Investment Management, LLC | Mutual Fund | 2026/Q3 | +319,979 | 0.1% |
| Renaissance Technologies Corp. | Hedge Fund | 2026/Q3 | +257,700 | 0.1% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +192,458 | 4.0% |
| Tema ETFs LLC | Mutual Fund | 2026/Q3 | +187,428 | 0.1% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +2,578,238 | 0.8% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +7,030,160 | 5.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +5,877,176 | 8.2% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q3 | +5,323,264 | 4.1% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 10 Nov 2026 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Sale | -191,303 | $8.09 | 604,144 |
| 10 Nov 2026 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Retained | +8,697 | $7.55 | 604,144 |
| 9 Nov 2026 | Daniel Kirby | Chief Commercial Officer | Derivative Exercise and Sale | -3,935 | $8.08 | 160,576 |
| 9 Nov 2026 | Daniel Kirby | Chief Commercial Officer | Derivative Exercise and Retained | +6,065 | – | 160,576 |
| 5 Nov 2026 | Corleen Roche | Chief Financial Officer | Derivative Exercise and Sale | -5,311 | $8.04 | 35,946 |
| 5 Nov 2026 | Corleen Roche | Chief Financial Officer | Derivative Exercise and Retained | +7,189 | – | 35,946 |
| 29 Sep 2026 | Noah Berkowitz | Chief Medical Officer | Other Derivative Acquisition | +135,000 | $14.82 | 135,000 |
| 29 Sep 2026 | Noah Berkowitz | Chief Medical Officer | Other Derivative Acquisition | +180,000 | – | 180,000 |
| 7 Sep 2026 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Sale | -3,976 | $8.70 | 142,074 |
| 7 Sep 2026 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Retained | +3,837 | – | 142,074 |
| 7 Sep 2026 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Sale | -6,638 | $8.70 | 595,447 |
| 7 Sep 2026 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Retained | +8,988 | – | 595,447 |
| 7 Sep 2026 | Raj Puri | Chief Regulatory Officer | Derivative Exercise and Sale | -4,478 | $8.70 | 256,364 |
| 7 Sep 2026 | Raj Puri | Chief Regulatory Officer | Derivative Exercise and Retained | +5,288 | – | 256,364 |
| 31 Aug 2026 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Sale | -4,472 | $8.28 | 138,237 |
| 31 Aug 2026 | Igor Bilinsky | Chief Operating Officer | Derivative Exercise and Retained | +4,317 | – | 138,237 |
| 31 Aug 2026 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Sale | -17,702 | $8.28 | 586,459 |
| 31 Aug 2026 | Frederick Vogt | Interim CEO, President, General Counsel, Corporate Secretary & Director | Derivative Exercise and Retained | +23,967 | – | 586,459 |
| 31 Aug 2026 | Raj Puri | Chief Regulatory Officer | Derivative Exercise and Sale | -2,508 | $8.28 | 251,076 |
| 31 Aug 2026 | Raj Puri | Chief Regulatory Officer | Derivative Exercise and Retained | +2,962 | – | 251,076 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 65,189,660 | 14.4% | 4.2 |
| 15 Oct 2026 | 58,925,298 | 13.0% | 4.4 |
| 30 Sep 2026 | 64,827,030 | 14.3% | 2.8 |
| 15 Sep 2026 | 87,127,871 | 19.2% | 7.4 |
| 31 Aug 2026 | 88,138,991 | 19.5% | 5.3 |
| 14 Aug 2026 | 102,940,590 | 22.7% | 4.8 |
No comments yet — be the first to weigh in on IOVA.
Sign in to join the discussion.